JP7760524B2 - 改善されたｔ細胞製造プロセス - Google Patents

改善されたｔ細胞製造プロセス

Info

Publication number
JP7760524B2
JP7760524B2 JP2022562606A JP2022562606A JP7760524B2 JP 7760524 B2 JP7760524 B2 JP 7760524B2 JP 2022562606 A JP2022562606 A JP 2022562606A JP 2022562606 A JP2022562606 A JP 2022562606A JP 7760524 B2 JP7760524 B2 JP 7760524B2
Authority
JP
Japan
Prior art keywords
cells
cell
population
seq
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562606A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021209759A5 (https=
JP2023521875A5 (https=
JP2023521875A (ja
Inventor
マーディロヴィッチ，カテリーナ
ハミルトン，ガース
Original Assignee
アダプティミューン・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダプティミューン・リミテッド filed Critical アダプティミューン・リミテッド
Publication of JP2023521875A publication Critical patent/JP2023521875A/ja
Publication of JPWO2021209759A5 publication Critical patent/JPWO2021209759A5/ja
Publication of JP2023521875A5 publication Critical patent/JP2023521875A5/ja
Application granted granted Critical
Publication of JP7760524B2 publication Critical patent/JP7760524B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022562606A 2020-04-17 2021-04-16 改善されたｔ細胞製造プロセス Active JP7760524B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005617.2 2020-04-17
GBGB2005617.2A GB202005617D0 (en) 2020-04-17 2020-04-17 Improved t cell manufacturing process
PCT/GB2021/050909 WO2021209759A1 (en) 2020-04-17 2021-04-16 Improved t cell manufacturing process

Publications (4)

Publication Number Publication Date
JP2023521875A JP2023521875A (ja) 2023-05-25
JPWO2021209759A5 JPWO2021209759A5 (https=) 2024-04-25
JP2023521875A5 JP2023521875A5 (https=) 2024-04-25
JP7760524B2 true JP7760524B2 (ja) 2025-10-27

Family

ID=70859978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562606A Active JP7760524B2 (ja) 2020-04-17 2021-04-16 改善されたｔ細胞製造プロセス

Country Status (7)

Country Link
US (1) US20230133064A1 (https=)
EP (1) EP4136216A1 (https=)
JP (1) JP7760524B2 (https=)
CN (1) CN115397975A (https=)
CA (1) CA3175266A1 (https=)
GB (1) GB202005617D0 (https=)
WO (1) WO2021209759A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN116496283B (zh) * 2022-01-18 2024-04-19 中国药科大学 五氮杂苊类化合物、制备方法、药物组合物和应用
JP2025515473A (ja) * 2022-04-28 2025-05-15 キュー バイオファーマ， インコーポレイテッド 改変された細胞傷害性ｔ細胞およびその使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
JP2018531026A (ja) 2015-10-20 2018-10-25 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｔ細胞療法用のｔ細胞を調製する方法
JP2018537970A (ja) 2015-11-05 2018-12-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 養子ｔ細胞療法のための細胞を調製する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3151672T1 (sl) * 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
JP2018531026A (ja) 2015-10-20 2018-10-25 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｔ細胞療法用のｔ細胞を調製する方法
JP2018537970A (ja) 2015-11-05 2018-12-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 養子ｔ細胞療法のための細胞を調製する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL FOR IMMUNOTHERAPY OF CANCER，2017年，Vol.5:26，pp.1-13

Also Published As

Publication number Publication date
GB202005617D0 (en) 2020-06-03
US20230133064A1 (en) 2023-05-04
WO2021209759A1 (en) 2021-10-21
EP4136216A1 (en) 2023-02-22
CN115397975A (zh) 2022-11-25
JP2023521875A (ja) 2023-05-25
CA3175266A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7760524B2 (ja) 改善されたｔ細胞製造プロセス
JP7181917B2 (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
US11905529B2 (en) Method of enhancing persistence of adoptively infused T cells
US20240374728A1 (en) T Cell Modification
JP7584437B2 (ja) 抗ｂｃｍａ ｃａｒ ｔ細胞の製造
TWI757785B (zh) 細胞激素誘導記憶型自然殺手細胞及其方法
WO2022229884A2 (en) Recombinant antigen presenting cells
JP2024538258A (ja) 高機能性自己幹由来のｔ細胞免疫療法
WO2022111451A1 (zh) Ras突变体表位肽及识别ras突变体的t细胞受体
AU2022292928A1 (en) Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use
WO2024206155A1 (en) Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
HK40117446A (en) T cell modification
JP2025516264A (ja) 多重化ｔ細胞受容体組成物、その併用療法、及び使用
HK40100476A (zh) 扩增t细胞群的方法
WO2025038745A1 (en) Compositions and methods for activating immune cells
WO2026007901A1 (zh) 共表达细胞因子的FLT3-CAR-γδT细胞及其应用
CN115772497A (zh) 一种靶向g12v突变kras的树突状细胞疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251015

R150 Certificate of patent or registration of utility model

Ref document number: 7760524

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150